Evidence map›Paper›PMID 26975008›Full record

ArticleClinical nuclear medicine2016

68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.

Christina Bluemel, Markus Krebs, Bülent Polat, Fränze Linke, Matthias Eiber, Samuel Samnick, Constantin Lapa, Michael Lassmann, Hubertus Riedmiller, Johannes Czernin and 6 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical nuclear medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05936658 (A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer), which is not on this map. Cited by 78 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 5 pooled it
29.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05936658 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

TypeinterventionalSponsorFutureChemRan2023 to 2025Enrolled138ConditionsHigh Risk Prostate CarcinomaArms[F-18]Florastamin
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 5 syntheses or guidelines pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Metaanalysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. World journal of urology · 2021
    Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Head-to-Head Comparison of [Current oncology (Toronto, Ont.) · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Christina BluemelFrom the Departments of *Nuclear Medicine, †Urology, and ‡Radiation Oncology, University Hospital of Würzburg, Würzburg; §Department of Radiation Oncology, Klinikum Ansbach, Ansbach; ∥Department of Nuclear Medicine, Technische Universität München, Munich, Germany; ¶Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; #Department of Nuclear Medicine-PET/CT Oncologic & Endocrine Sections, Rovigo Hospital, Rovigo, Italy; **Department of Radiology, University Hospital of Würzburg, Würzburg, Germany; ††Scintomics GmbH, Fürstenfeldbruck; and ‡‡Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
Markus Krebs
Bülent Polat
Fränze Linke
Matthias Eiber
Samuel Samnick
Constantin Lapa
Michael Lassmann
Hubertus Riedmiller
Johannes Czernin
Domenico Rubello
Thorsten Bley
Saskia Kropf
Hans-Juergen Wester
Andreas K Buck
Ken Herrmann
Universitätsklinikum Würzburg · DE

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of MelanomaP01CA132681 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI WANG, PIN · 2010 to 2014
$14.4M
NCI NIH HHS P01 CA132681NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

purposeInvestigating the value of Ga-PSMA-PET/CT in biochemically recurring prostate cancer patients with negative F-choline-PET/CT. PATIENTS AND

methodsOne hundred thirty-nine consecutive patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy were offered participation in this sequential clinical imaging approach. Patients first underwent an F-choline-PET/CT. If negative, an additional Ga-PSMA-PET/CT was offered. One hundred twenty-five of 139 eligible patients were included in the study; 32 patients underwent additional Ga-PSMA-PET/CT. Patients with equivocal findings (n = 5) on F-choline-PET/CT and those who declined the additional Ga-PSMA-PET/CT (n = 9) were excluded. Images were analyzed visually for the presence of suspicious lesions. Findings on PET/CT were correlated with PSA level, PSA doubling time (dt), and PSA velocity (vel).

resultsThe overall detection rates were 85.6% (107/125) for the sequential imaging approach and 74.4% (93/125) for F-choline-PET/CT alone. Ga-PSMA-PET/CT detected sites of recurrence in 43.8% (14/32) of the choline-negative patients. Detection rates of the sequential imaging approach and F-choline-PET/CT alone increased with higher serum PSA levels and PSA vel. Subgroup analysis of Ga-PSMA-PET/CT in F-choline negative patients revealed detection rates of 28.6%, 45.5%, and 71.4% for PSA levels of 0.2 or greater to less than 1 ng/mL, 1 to 2 ng/mL, and greater than 2 ng/mL, respectively.

conclusionsThe sequential imaging approach designed to limit Ga-PSMA imaging to patients with negative choline scans resulted in high detection rates. Ga-PSMA-PET/CT identified sites of recurrent disease in 43.8% of the patients with negative F-choline PET/CT scans.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIAgedAged, 80 and overCholineGallium RadioisotopesHumansMaleMiddle AgedNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProstatic NeoplasmsAntigens, SurfaceCholinefluoromethylcholineFOLH1 protein, humanGallium RadioisotopesGlutamate Carboxypeptidase II

Identifiers

PMID26975008
PMCPMC5006491
OpenAlexW2299477037

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.